Bifidobacterium adolescentis DSM 20083

Bifidobacterium adolescentis DSM 20083 is a specific strain of gram-positive anaerobic bacteria classified under the Bifidobacterium genus, characterized by its bifid morphology and production of acetate and lactate via the fructose-6-phosphate phosphoketolase (F6PPK) pathway. No strain-specific clinical trials exist for DSM 20083, though the broader B. adolescentis species is studied for its capacity to ferment arabinoxylan, xylooligosaccharides (XOS), and galactooligosaccharides (GOS) into short-chain fatty acids.

Origin & History

Bifidobacterium adolescentis DSM 20083 is a specific strain of anaerobic, Gram-positive bacterium isolated from the human adult intestine before 1990. It is maintained as a type strain (also known as ATCC 15703 or E194a variant) in culture collections and is cultured anaerobically for probiotic applications.

Historical & Cultural Context

No historical or traditional medicine use is documented for Bifidobacterium adolescentis DSM 20083. It is a modern isolate from the pre-1990 era studied primarily in probiotic and microbiome research contexts.

Health Benefits

• No clinical evidence available - species-level research suggests potential for short-chain fatty acid production, but strain-specific benefits unproven
• No clinical evidence available - general B. adolescentis strains studied for prebiotic metabolism (arabinoxylan, XOS, GOS), but no data for DSM 20083
• No clinical evidence available - species may contribute to GABA production, but strain-specific activity unconfirmed
• No clinical evidence available - potential B-vitamin synthesis (e.g., folic acid) noted at species level only
• No clinical evidence available - limited resistant starch degradation (2.8% ± 2.1%) observed in vitro only

How It Works

B. adolescentis DSM 20083 metabolizes non-digestible dietary fibers through the fructose-6-phosphate phosphoketolase (F6PPK) pathway, yielding acetate, lactate, and formate as primary fermentation end-products. The strain expresses carbohydrate-active enzymes (CAZymes), including arabinofuranosidases and xylanases, enabling hydrolysis of arabinoxylan and xylooligosaccharides into fermentable monosaccharides. Resulting short-chain fatty acids, particularly acetate, may interact with colonic epithelial G-protein-coupled receptors GPR41 and GPR43, influencing gut barrier integrity and local immune signaling, though these effects are inferred from species-level data and not confirmed for DSM 20083 specifically.

Scientific Research

No human clinical trials, RCTs, or meta-analyses are available for Bifidobacterium adolescentis DSM 20083. The research consists solely of in-vitro characterization studies examining morphology and resistant starch degradation capabilities.

Clinical Summary

No published clinical trials have investigated Bifidobacterium adolescentis DSM 20083 as a standalone intervention in human subjects. At the species level, B. adolescentis strains have been evaluated in small in vitro fermentation studies and limited human microbiome research, primarily examining prebiotic substrate metabolism rather than measurable health endpoints. A 2012 study by Van den Abbeele et al. using a mucosal simulator of the human intestinal microbial ecosystem (M-SHIME) demonstrated B. adolescentis enrichment following arabinoxylan supplementation, but this was a model system with no direct clinical outcomes. Given the absence of randomized controlled trials, any health benefits attributed to DSM 20083 specifically remain speculative and unsupported by clinical evidence.

Nutritional Profile

Bifidobacterium adolescentis DSM 20083 is a probiotic bacterial strain delivered in non-nutritive quantities (typically 1–10 billion CFU per serving), contributing negligible macronutrients (protein, fat, carbohydrates) or caloric value to the diet. The cells themselves contain bacterial structural components including peptidoglycan cell wall polymers, lipoteichoic acids, and exopolysaccharides. As a metabolically active fermentative organism, B. adolescentis species are known producers of short-chain fatty acids (SCFAs), primarily acetate and lactate as primary fermentation end-products, with minor formate production; butyrate production is minimal compared to species like B. longum. Species-level data indicates capacity for B-vitamin biosynthesis, particularly folate (vitamin B9) and riboflavin (vitamin B2), though strain-specific yields for DSM 20083 have not been quantified in published literature. The strain carries carbohydrate-active enzymes (CAZymes) enabling metabolism of arabinoxylan, xylo-oligosaccharides (XOS), and galacto-oligosaccharides (GOS), generating fermentation byproducts in situ. Species within B. adolescentis possess glutamate decarboxylase (GAD) enzyme activity associated with GABA biosynthesis from glutamate, but quantitative GABA output for DSM 20083 specifically is unreported. No direct mineral, fat-soluble vitamin, or fiber content is contributed by this ingredient at probiotic dosing levels.

Preparation & Dosage

No clinically studied dosage ranges are available for Bifidobacterium adolescentis DSM 20083 in any form. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bifidobacterium strains, Prebiotics (XOS, GOS, arabinoxylan), Lactobacillus species, Dietary fiber

Safety & Interactions

Bifidobacterium adolescentis DSM 20083 has not been independently evaluated in formal human safety or tolerability trials, so a comprehensive safety profile specific to this strain does not exist. Bifidobacterium species broadly are classified as Generally Recognized As Safe (GRAS) by the FDA and carry Qualified Presumption of Safety (QPS) status from EFSA, suggesting a low inherent risk in healthy adults. Individuals who are immunocompromised, post-surgical, or have compromised gut mucosal integrity should exercise caution with any probiotic strain, as rare cases of bacteremia have been reported with Bifidobacterium spp. in vulnerable populations. No documented drug interactions or contraindications specific to DSM 20083 are established; concurrent antibiotic use may reduce viability of the strain if administered simultaneously.